BIOLUX P-III Passeo-18Lux All-Comers Registry: 24-Month Results in Below-the-Knee Arteries.

Abstract

The BIOLUX P-III registry was initiated to further assess the safety and efficacy of the Passeo-18Lux drug-coated balloon (DCB) in infrainguinal lesions in a real-world environment and in prespecified risk groups. BIOLUX P-III is a prospective, global, all-comers registry with patients treated under real-world conditions. We herein report 24-month results of the prespecified subgroup of 151 patients with 185 below-the-knee (BTK) lesions. The primary safety and efficacy endpoints were freedom from major adverse events (a composite of freedom from device and procedure mortality through 30days, major target limb amputation and clinically driven target lesion revascularization) at 6months and freedom from clinically driven target lesion revascularization (FfTLR) at 12months. At baseline, 76.0% of patients had critical limb ischemia and 48.9% of lesions were TASC C or D lesions. Technical success was achieved in 97.8%, and bailout stenting was required in 1.1%. Freedom from major adverse events was 86.2% [95% CI 79.4; 90.8] at 6months, and FfTLR was 90.9% [95% CI 85.2; 94.4] at 12months. At 24months, FfTLR was 90.9% [95% CI 85.2; 94.4], freedom from major amputation was 90.1% [95% CI 83.9, 94.0], and overall survival was 79.2% [70.7, 85.5]. There was a significant clinical improvement (mean Rutherford class improvement of - 2.9 ± 1.9, p < 0.0001) and an improvement in pain (mean improvement on Wong-Baker Faces Pain Scale of - 2.7 ± 2.9, p < 0.0001). In this real-world DCB registry, 24-month outcomes of Passeo-18Lux demonstrated safety and efficacy in BTK lesions with high patency rates and sustained clinical improvements at 24months. NCT02276313.